Arcutis announces results of survey on inflammatory skin conditions

Arcutis Biotherapeutics (ARQT) announced results of Skin Insights: Steroid Perceptions in Chronic Inflammatory Skin Diseases, a nationwide survey of adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. The survey was designed to understand patient and parent perceptions and behaviors around the use of topical steroids, as well as perspectives on short-term, reactive treatments versus long-term, proactive disease management. “There’s a growing consensus across the dermatology community that long-term use of topical steroids can carry serious local as well as systemic risks, and there is a desire to move away from episodic care towards more proactive disease management,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis. “These survey findings highlight the real-world challenges adults and parents of children with these conditions face in managing chronic skin diseases and reinforce the need for treatment options that go beyond cyclical care and deliver effective, sustained relief – underscoring the urgent need to redefine what standard of care should look like.”